Shackelford Pharma Inc.
OperatingBiotech · Vancouver
Financials
FY2019–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Dec 9, 2022| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Shares | 45,463,767 | — | 100.0% | $1.00May 2020 |
Sold to the crowd
- Reg A+ · May 20208,857,288 Common Shares at $1.00$8.9M
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
5 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 24 filings on EDGAR- Form 1-KJan 24, 20250001062993-25-001051EDGAR
- Form 1-UApr 30, 20240001062993-24-009062EDGAR
- Form 1-KJan 30, 20240001062993-24-001528EDGAR
- Form 1-SAJun 29, 20230001062993-23-014122EDGAR
- Form 253G2Feb 2, 20230001062993-23-001894EDGAR
- Form 1-KJan 30, 20230001062993-23-001582EDGAR
- Form 253G2Jan 24, 20230001062993-23-001309EDGAR
- Form 253G2Jan 23, 20230001062993-23-001228EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.